Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed a Next Day Disclosure Return detailing the repurchase of 53,500 H shares on 5 October 2026.

Key transaction details • Volume: 53,500 H shares (0.016 % of issued shares excluding treasury stock) • Price range: HKD 21.06–HKD 21.30 per share; volume-weighted average repurchase price recorded at RMB 21.1662 per share • Aggregate consideration: HKD 1.13 million • Repurchase method: On-market transactions on the Stock Exchange of Hong Kong • Shares will be held as treasury stock; no cancellation announced

Capital structure after the repurchase (5 October 2026) • Issued shares (excluding treasury): 322.12 million • Treasury shares: 14.23 million • Total issued shares (including treasury): 336.35 million • Treasury shares now represent 4.23 % of total issued capital, up from 4.22 % before the transaction.

Repurchase mandate utilisation • Authorised limit (granted 13 May 2026): 32.72 million shares • Cumulative shares repurchased to date: 5.34 million, equal to 16.32 % of the mandate and 1.59 % of shares outstanding at the mandate date.

Post-buyback restrictions Under Hong Kong listing rules, Zylox-Tonbridge is subject to a moratorium on issuing new shares or disposing of treasury shares until 4 November 2026.

The company confirmed that the repurchase complied with all applicable Hong Kong Stock Exchange listing rules and relevant regulatory requirements.